Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 5Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Classical hematology 5Lymphoid 1

Conditions

Breast Neoplasms 591Neoplasms 296Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 266Colorectal Neoplasms 213Multiple Myeloma 182Lung Neoplasms 150Neoplasm Metastasis 139Leukemia, Myeloid, Acute 126Leukemia 120Lymphoma 114Lymphoma, Follicular 113Stomach Neoplasms 105Lymphoma, Non-Hodgkin 102Colonic Neoplasms 98Ovarian Neoplasms 96Rectal Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 94Uterine Cervical Neoplasms 93Head and Neck Neoplasms 92Leukemia, Lymphocytic, Chronic, B-Cell 91Pain 90Carcinoma, Hepatocellular 86Pancreatic Neoplasms 81Melanoma 78Lymphoma, Large B-Cell, Diffuse 77Papillomavirus Infections 68Recurrence 66Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 63

Interventions

emicizumab 4Factor VIII 2recombinant FVIIa 1anti-inhibitor coagulant complex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Completed × Hemophilia A × Clear all
NCT03020160 2023-01-11

HAVEN 4

Hoffmann-La Roche

Phase 3 Completed
48 enrolled 44 charts 1 FDA
Classical hematology

Hemophilia A

NCT02847637 2022-11-16

HAVEN 3

Hoffmann-La Roche

Phase 3 Completed
152 enrolled 46 charts 1 FDA
Classical hematology

Hemophilia A

NCT02622321 2021-06-24

HAVEN 1

Hoffmann-La Roche

Phase 3 Completed
113 enrolled 45 charts 1 FDA
Classical hematology

Hemophilia A

NCT02795767 2021-06-02

HAVEN 2

Hoffmann-La Roche

Phase 3 Completed
88 enrolled 65 charts 1 FDA
Classical hematology

Hemophilia A

NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡